Publication
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (14)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 14
- cancerMalignant Prostate Neoplasmcivic_curation1.00
- drugOlaparibcivic_curation1.00
- geneATMcivic_curation1.00
- geneBRCA1civic_curation1.00
- geneBRCA2civic_curation1.00
- geneMRE11civic_curation1.00
- genePALB2civic_curation1.00
- variantATM Mutationcivic_curation1.00
- variantATM N2875Hcivic_curation1.00
- variantATM S2289*civic_curation1.00
- variantBRCA1 Loss-of-functioncivic_curation1.00
- variantBRCA2 Loss-of-functioncivic_curation1.00
- variantMRE11 Frameshiftcivic_curation1.00
- variantPALB2 Biallelic Inactivationcivic_curation1.00
Curated evidence
Evidence citing this paper (8)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26510020
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ATM Mutation1 | ||||||||
| Olaparib | Malignant Prostate Neoplasm | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1960Response to olaparib was observed in 4 of 5 with prostate cancer patients with ATM aberrations (2 germline). PMID 26510020 · Mateo et al., 2015 · Open in CIViC | civic |
| ATM N2875H1 | ||||||||
| Olaparib | Malignant Prostate Neoplasm | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID648Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Over… (full text at CIViC) PMID 26510020 · Mateo et al., 2015 · Open in CIViC | civic |
| ATM S2289*1 | ||||||||
| Olaparib | Malignant Prostate Neoplasm | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID647Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Over… (full text at CIViC) PMID 26510020 · Mateo et al., 2015 · Open in CIViC | civic |
| BRCA1 Loss-of-function1 | ||||||||
| Olaparib | Malignant Prostate Neoplasm | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID8451/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study. PMID 26510020 · Mateo et al., 2015 · Open in CIViC | civic |
| BRCA2 Loss-of-function1 | ||||||||
| Olaparib | Malignant Prostate Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID650In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function al… (full text at CIViC) PMID 26510020 · Mateo et al., 2015 · Open in CIViC | civic |
| MRE11 Frameshift1 | ||||||||
| Olaparib | Malignant Prostate Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1016One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11, ATM, MLH3 and NBN genes and showed clinical response to PARP inhibitor olaparib (16 weeks… (full text at CIViC) PMID 26510020 · Mateo et al., 2015 · Open in CIViC | civic |
| MRE11 Loss1 | ||||||||
| Unspecified therapy | Malignant Prostate Neoplasm | Predictive | C | Supports Sensitivity Response | 2 | rejected | EID877One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11 gene and showed clinical response to PARP inhibitor olaparib. PMID 26510020 · Mateo et al., 2015 · Open in CIViC | civic |
| PALB2 Biallelic Inactivation1 | ||||||||
| Olaparib | Malignant Prostate Neoplasm | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1963From 14 prostate cancer patients (88%) who had a response to olaparib, 7 patients had BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations), 4 of 5 with had ATM aberrations and one… (full text at CIViC) PMID 26510020 · Mateo et al., 2015 · Open in CIViC | civic |